GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial

GeoVax Labs, Inc.

Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.
BARDA Project NextGen award for GEO-CM04S1 Phase 2b trial; total value $367-388M incl. Allucent.
Cash $1.56M at June 30, 2024, down from $6.45M at Dec 31, 2023.
Gedeptin advanced to expanded Phase 2 trial for head and neck cancer; activation H1 2025.
Commercial manufacturing platform for GEO-CM04S1 established with Oxford Biomedica.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.